NUVOLA, GIACOMO
NUVOLA, GIACOMO
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
2023 Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Tateo, Valentina; Nuvola, Giacomo; Rizzo, Alessandro; Massari, Francesco; Mollica, Veronica
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis
2023 Rizzo, Alessandro; Nuvola, Giacomo; Palmiotti, Gennaro; Ahcene-Djaballah, Selma; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Nigro, Maria Concetta; Tassinari, Elisa; Macrini, Sveva; Massari, Francesco
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy
2022 Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022 Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F.
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022 Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F.
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
2022 Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F.
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
2022 Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti G.; Campana D.
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem?
2022 Nuvola G.; Rizzo A.; Mollica V.; Massari F.
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
2022 Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M.
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt
2021 Mollica V.; Marchetti A.; Rosellini M.; Nuvola G.; Rizzo A.; Santoni M.; Cimadamore A.; Montironi R.; Massari F.
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases
2021 Di Nunno Vincenzo; Nuvola Giacomo; Mosca Mirta; Maggio Ilaria; Gatto Lidia; Tosoni Alicia; Lodi Raffaele; Franceschi Enrico; Brandes Alba Ariela
Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma
2021 DM, Filippini; G, Nuvola; M, Nannini; M, Saponara; S, Cammelli; Paolis M, De; AM, Perrone; Iaco P, De; Leo A, De; A, Astolfi; MA, Pantaleo
IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
2021 Di Federico, A.; Nuvola, G.; Deiana, C.; Donati, G.; De Giglio, A.
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis
2021 Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A.
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution
2021 Di Federico A.; Andrini E.; Sisi M.; Nuvola G.; Lamberti G.; Lenzi B.; Nobili E.; Gelsomino F.; Ardizzoni A.
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
2021 De Giglio, A.; Di Federico, A.; Nuvola, G.; Deiana, C.; Gelsomino, F.
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory?
2021 Marchetti A.; Rosellini M.; Mollica V.; Rizzo A.; Tassinari E.; Nuvola G.; Cimadamore A.; Santoni M.; Fiorentino M.; Montironi R.; Massari F.
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics
2020 de Giglio, A.; Nuvola, G.; Baldini, C.
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A.
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
2020 Di Federico A.; Nuvola G.; Sisi M.; Lenzi B.; Nobili E.; Campana D.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma | Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Tateo, Valentina; Nuvola, Giacomo; Rizzo,... Alessandro; Massari, Francesco; Mollica, Veronica | 2023-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis | Rizzo, Alessandro; Nuvola, Giacomo; Palmiotti, Gennaro; Ahcene-Djaballah, Selma; Mollica, Veronic...a; Rosellini, Matteo; Marchetti, Andrea; Nigro, Maria Concetta; Tassinari, Elisa; Macrini, Sveva; Massari, Francesco | 2023-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy | Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa...; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco | 2022-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study | Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; My...int Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | Cancers 2022 [MOUSEION04].pdf; cancers-14-04142-s001.zip |
| Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw | Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.;... Massari F. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Current Oncology 2022 [Bone agents PCa].pdf |
| Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer | Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F. | 2022-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | - |
| Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis | Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti... G.; Campana D. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Vescica_SEER.pdf; curroncol-29-00461-s001.zip |
| The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem? | Nuvola G.; Rizzo A.; Mollica V.; Massari F. | 2022-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy | Tassinari E.; Mollica V.; Nuvola G.; Marchetti A.; Massari F.; Rosellini M. | 2022-01-01 | CANCER MANAGEMENT AND RESEARCH | - | 1.01 Articolo in rivista | CMAR 2022 [Eli UC after first line].pdf |
| An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt | Mollica V.; Marchetti A.; Rosellini M.; Nuvola G.; Rizzo A.; Santoni M.; Cimadamore A.; Montironi... R.; Massari F. | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | ijms-22-13519-v2.pdf |
| Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases | Di Nunno Vincenzo; Nuvola Giacomo; Mosca Mirta; Maggio Ilaria; Gatto Lidia; Tosoni Alicia; Lodi R...affaele; Franceschi Enrico; Brandes Alba Ariela | 2021-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma | DM, Filippini; G, Nuvola; M, Nannini; M, Saponara; S, Cammelli; Paolis M, De; AM, Perrone; Iaco P..., De; Leo A, De; A, Astolfi; MA, Pantaleo | 2021-01-01 | Journal of Cancer Science and Clinical Therapeutics | - | 1.01 Articolo in rivista | - |
| IMpower 132: Is the Second Exception to the Rule No Longer an Exception? | Di Federico, A.; Nuvola, G.; Deiana, C.; Donati, G.; De Giglio, A. | 2021-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis | Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A. | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution | Di Federico A.; Andrini E.; Sisi M.; Nuvola G.; Lamberti G.; Lenzi B.; Nobili E.; Gelsomino F.; A...rdizzoni A. | 2021-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | acd-32-755.pdf |
| The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) | De Giglio, A.; Di Federico, A.; Nuvola, G.; Deiana, C.; Gelsomino, F. | 2021-01-01 | CURRENT ONCOLOGY REPORTS | - | 1.01 Articolo in rivista | - |
| The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? | Marchetti A.; Rosellini M.; Mollica V.; Rizzo A.; Tassinari E.; Nuvola G.; Cimadamore A.; Santoni... M.; Fiorentino M.; Montironi R.; Massari F. | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | ijms-22-06237-v2.pdf |
| Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics | de Giglio, A.; Nuvola, G.; Baldini, C. | 2020-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience | Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppion...i E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A. | 2020-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? | Di Federico A.; Nuvola G.; Sisi M.; Lenzi B.; Nobili E.; Campana D. | 2020-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |